What is the story about?
What's Happening?
The IMA Group has announced the acquisition of the Chicago Research Center (CRC), a clinical research site specializing in central nervous system (CNS) and sleep disorders. This acquisition marks IMA's first entry into sleep research, addressing a significant public health need as sleep disorders affect millions of Americans. CRC, founded in 2005, operates a dedicated sleep lab and has conducted over 125 studies in CNS and sleep disorders. The acquisition aims to expand IMA's research capacity and accelerate the development of therapies for sleep-related conditions. CRC will continue to operate under its current leadership, maintaining its focus on CNS and sleep research.
Why It's Important?
The acquisition of CRC by IMA Group is significant as it addresses the growing need for research in sleep disorders, which affect a substantial portion of the U.S. population. By expanding its research capabilities, IMA aims to improve access to innovative treatments for sleep disorders, potentially benefiting millions of Americans who suffer from conditions like insomnia and sleep apnea. This move also strengthens IMA's position in the clinical research industry, enhancing its ability to conduct diverse trials and support the development of new therapies across multiple therapeutic areas.
What's Next?
Following the acquisition, IMA Group plans to expand its sleep research capabilities across additional sites, further increasing its trial capacity and diversity. This strategic expansion is expected to strengthen sponsor relationships and contribute to urgent needs in sleep and mental health research. IMA's broader reach in clinical trials, including obesity, diabetes, and cardiovascular disease, will continue to support diverse patient populations and meet the needs of sponsors nationwide.
AI Generated Content
Do you find this article useful?
